X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATI-1777 is an investigational topical soft JAK 1/3 inhibitor, small molecule drug. It is under phase 2 clinical development for the treatment of mild to severe atopic dermatitis.
Lead Product(s): ATI-1777
Therapeutic Area: Dermatology Product Name: ATI-1777
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Licensing Agreement December 05, 2023
Details:
ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor for the treatment of Moderate to Severe Rheumatoid Arthritis.
Lead Product(s): Zunsemetinib,Methotrexate
Therapeutic Area: Immunology Product Name: ATI-450
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
ATI-1777 is a topical JAK inhibitor designed to minimize systemic exposure and delivered in a spray-on solution, which is investigated for the treatment of mild to severe atopic dermatitis.
Lead Product(s): ATI-1777
Therapeutic Area: Dermatology Product Name: ATI-1777
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases.
Lead Product(s): ATI-2138
Therapeutic Area: Gastroenterology Product Name: ATI-2138
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor for the treatment of Moderate to Severe Rheumatoid Arthritis.
Lead Product(s): Zunsemetinib,Methotrexate
Therapeutic Area: Immunology Product Name: ATI-450
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 inhibitor. This mechanism potentially leads to the inhibition of inflammatory signals. It is being developed for rheumatoid arthritis and psoriatic arthritis.
Lead Product(s): Zunsemetinib
Therapeutic Area: Dermatology Product Name: ATI-450
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
ATI-2138 is an investigational oral compound being developed for the treatment of autoimmune diseases. It inhibits both T-cell and cytokine receptors which may potentially treat T-cell mediated autoimmune diseases.
Lead Product(s): ATI-2138
Therapeutic Area: Immunology Product Name: ATI-2138
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China.
Lead Product(s): ATI-1777
Therapeutic Area: Dermatology Product Name: ATI-1777
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pediatrix Therapeutics
Deal Size: $96.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement November 29, 2022
Details:
Under the agreement, Aclaris granted Lilly non-exclusive rights under patents and patent applications that Aclaris exclusively licenses from The Trustees of Columbia University, for the use of Olumiant (baricitinib), Lilly’s JAK inhibitor, to treat alopecia areata (AA).
Lead Product(s): Baricitinib
Therapeutic Area: Dermatology Product Name: Olumiant
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
